Objective: The Genomics Shared Resource provides state-of-the-art facilities, technical support and services for scalable, innovative analysis of genetic variation and function, putting University of Colorado Cancer Center (UCCC) members on the cutting edge of cancer research. Services and Technologies: We use Affymetrix and lllumina oligonucleotide arrays and quantitative DNA/RNA methodologies to investigate gene expression/regulation changes, genotyping, and copy number variation. The GSR incorporates several platforms, including Affymetrix (with GeneTitan), lllumina (with iScan and HiSeq 2000), Agilent, and Combimatrix, establishing a comprehensive genomics research capacity, including expression, exon, tiling, re-sequencing and SNP/CNV, as well as custom design array services through collaboration with combimatrix por agilent Selected genes are analyzed using a Beckman Coulter GenomeLab GeXP genetic analysis system and Applied Biosystems real time PCR technology. For microarray data analysis, we provide members access to Partek Genomics Suite; GeneSpring; and Ingenuity pathway system and frequently use online public resources, including R and Bioconductor. More complex genomics data analysis is available to members through the Biostatistics and Bioinformatics Shared Resource. Consultation and Training: The GSR provides consultation for designing and analyzing excellent, reliable genomics experiments and helps keep members up to date as technology advances. Utilization: The Genomics Shared Resource is one of the highest volume academic Affymetrix microarray facilities in the country, having performed over 16,000 microarrays, including test arrays, for nearly 350 investigators over 10 years. Data from the Shared resource has been incorporated into over 300 published manuscripts to date. Management and Finances: This resource is UCCC-managed. Currently, 9% of the operating budget comes from CCSG support and 52% from chargebacks to UCCC members who represent 86% of users in 2010. The GSR requests $169,541 of CCSG support for 11% of its operating budget Future directions for the Genomics Shared Resource include upgraded microarray technologies, developing capacity with the newly-acquired lllumina HiSeq 2000 sequencer, moving into third generation sequencing possibly through the Pacific Biosciences Single Molecule Real Time (SMRT) DNA sequencing technology, and using highthroughput genetic analysis in translational research.
The Genomics Shared Resource provides consultation and service for advanced, state-of-the-art microarray and Next Generation (NextGen) DNA sequencing technology for translational cancer research. The GSR's comprehensive genomics research capacity, including expression, exon, tiling, re-sequencing and SNP/CNV arrays for studying gene expression/regulation changes, genotyping, and copy number variation is one of the most heavily used UCCC research resources, having supported nearly 350 investigators to date.
|Ren, Shengxiang; Rivard, Christopher J; Yu, Hui et al. (2018) A miRNA Panel Predicts Sensitivity of FGFR Inhibitor in Lung Cancer Cell Lines. Clin Lung Cancer 19:450-456|
|Donson, Andrew M; Amani, Vladimir; Warner, Elliot A et al. (2018) Identification of FDA-Approved Oncology Drugs with Selective Potency in High-Risk Childhood Ependymoma. Mol Cancer Ther 17:1984-1994|
|Branchford, B R; Stalker, T J; Law, L et al. (2018) The small-molecule MERTK inhibitor UNC2025 decreases platelet activation and prevents thrombosis. J Thromb Haemost 16:352-363|
|Pei, Shanshan; Minhajuddin, Mohammad; Adane, Biniam et al. (2018) AMPK/FIS1-Mediated Mitophagy Is Required for Self-Renewal of Human AML Stem Cells. Cell Stem Cell 23:86-100.e6|
|Ryan, Weston Kenneth; Fernandez, Josiah; Peterson, Mikayla Katherine et al. (2018) Activation of S6 signaling is associated with cell survival and multinucleation in hyperplastic skin after epidermal loss of AURORA-A Kinase. Cell Death Differ :|
|Monks, Jenifer; Orlicky, David J; Stefanski, Adrianne L et al. (2018) Maternal obesity during lactation may protect offspring from high fat diet-induced metabolic dysfunction. Nutr Diabetes 8:18|
|Garcia, Tamara B; Fosmire, Susan P; Porter, Christopher C (2018) Increased activity of both CDK1 and CDK2 is necessary for the combinatorial activity of WEE1 inhibition and cytarabine. Leuk Res 64:30-33|
|Wahdan-Alaswad, R S; Edgerton, S M; Salem, H S et al. (2018) Metformin Targets Glucose Metabolism in Triple Negative Breast Cancer. J Oncol Transl Res 4:|
|Oweida, Ayman; Phan, Andy; Vancourt, Benjamin et al. (2018) Hypofractionated Radiotherapy Is Superior to Conventional Fractionation in an Orthotopic Model of Anaplastic Thyroid Cancer. Thyroid 28:739-747|
|Gadalla, Shahinaz M; Wang, Tao; Loftus, David et al. (2018) No association between donor telomere length and outcomes after allogeneic unrelated hematopoietic cell transplant in patients with acute leukemia. Bone Marrow Transplant 53:383-391|
Showing the most recent 10 out of 1634 publications